BCL2 and AL amyloidosis: The results of our multicenter observational study demonstrate that Venetoclax can induce rapid, deep and durable hematologic responses, resulting in a clinically meaningful, consistent improvement in organ function, in patients with relapsed/refractory AL amyloidosis with t(11;14) and BCL2 expression.